Quercetin with the potential effect on allergic diseases

• Review
• Open Access
• 
  

• Morteza Jafarinia, 
• Mahnaz Sadat Hosseini, 
• Neda kasiri, 
• Niloofar Fazel, 
• Farshid Fathi, 
• Mazdak Ganjalikhani Hakemi & 
• Nahid Eskandari 

Allergy, Asthma & Clinical Immunology volume 16, Article number: 36 (2020) Cite this article

• details

Abstract

Quercetin is a naturally occurring polyphenol flavonoid which is rich in antioxidants. It has anti-allergic functions that are known for inhibiting histamine production and pro-inflammatory mediators. Quercetin can regulate the Th1/Th2 stability, and decrease the antigen-specific IgE antibody releasing by B cells. Quercetin has a main role in anti-inflammatory and immunomodulatory function which makes it proper for the management of different diseases.

3 categories of SARCoV2 testing - Infographic

Spacers and Valved Holding Chambers—The Risk of Switching to Different Chambers

REVIEW AND FEATURE ARTICLE

VOLUME 8, ISSUE 5, P1569-1573, MAY 01, 2020

Federico Lavorini, MD, PhD Celeste Barreto, MD, Job F.M. van Boven, PhD, Will Carroll, MD, Joy Conway, PhD, Richard W. Costello, MD, Birthe Hellqvist Dahl, PhD, Richard P.N. Dekhuijzen, MD, Stephen Holmes, MD, Mark Levy, MD, Mathieu Molimard, MD, PhD, Nicholas Roche, MD, PhD, Miguel Román-Rodriguez, MD, Nicola Scichilone, MD, Jane Scullion, MSc, Omar S. Usmani, MD, PhD

Abstract

Spacers are pressurized metered-dose inhaler (pMDI) accessory devices developed to reduce problems of poor inhaler technique with pMDIs. Spacers that feature a 1-way inspiratory valve are termed valved holding chambers (VHCs);

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

• EBioMedicine
• v.50; 2019 Dec
• PMC6921329

EBioMedicine. 2019 Dec; 50: 421–432.

Published online 2019 Nov 28. doi: 10.1016/j.ebiom.2019.11.006

PMCID: PMC6921329

PMID: 31786130

Julia Eckl-Dorna,a Milena Weber,b Victoria Stanek,a Birgit Linhart,b Robin Ristl,c Eva E. Waltl,a Sergio Villazala-Merino,a Andrea Hummel,a Margarete Focke-Tejkl,b Renate Froeschel,d Angela Neubauer,e Rainer Henning,e Thomas Perkmann,d Rudolf Valenta,b,f,g,⁎ and Verena Niederbergera

Associated Data

Supplementary Materials

Abstract

Background

BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins

Application of probiotics in adjuvant treatment of infant allergic rhinitis

RESEARCH ARTICLE: STUDY PROTOCOL CLINICAL TRIAL
A randomized controlled study

Cao, Xueqiu MDa,b; Zhong, Ping MDa; Li, Gang MDa; Zhu, Jiao MDa; Zheng, Yun PhDa,∗Author Information
Medicine: May 2020 - Volume 99 - Issue 18 - p e20095
doi: 10.1097/MD.0000000000020095

• OPEN

Abstract
Background:
Several studies have suggested that intestinal flora may play an important role in allergic diseases. The purpose of this study was to investigate the effect of probiotics of Bifidobacterium triplex on the symptoms of allergic rhinitis (AR).

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs

• Review
• Open Access
• 
  

Clinical and Translational Allergy

• O. Pfaar, 
• R. Gerth van Wijk, 
• L. Klimek, 
• J. Bousquet & 
• P. S. Creticos 

Clinical and Translational Allergy volume 10, Article number: 11 (2020) 

• details

Abstract

Allergen immunotherapy (AIT) is the only treatment option available for allergic patients with disease-modifying intention. Both efficacy and safety has been demonstrated for multiple trials in children, adolescents and adults. Though regulatory requirements for marketing authorization have been clearly outlined and an increasing number of high quality trials has been initiated, multiple concepts and details in study design may be further elaborated, harmonized and improved.

Prognostic factors for ARDS: clinical, physiological and atypical immunodeficiency

• BMC Pulmonary Medicine
• Research article
• Open Access
• 
  

• Min Song, 
• Yijie Liu, 
• Zhiwen Lu, 
• Hong Luo, 
• Hong Peng & 
• Ping Chen 

BMC Pulmonary Medicine volume 20, Article number: 102 (2020) 

• details

Abstract

Background

Relationships between the lymphocyte/neutrophil ratio and age,
APACHE II score, SOFA score, and PaO2/FiO2 ratio in ARDS patients

Risk factors affecting the prognosis of acute respiratory distress syndrome (ARDS) in adults were investigated. The aim was to identify new predictors for ARDS patient prognosis, including those with clinical, pathophysiological, and atypical immunodeficiency.

Methods

ARDS patients were retrospectively included. The patients were grouped and analysed according to different oxygenation index grades and prognosis, and factors influencing prognosis and survival were examined. Adolescent patients, patients with typical immunodeficiency and patients who died within 24 h after being diagnosed with ARDS were excluded. The predictive value for mortality was determined by Cox proportional hazard analysis.

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

Original Investigation

A Systematic Review and Network Meta-analysis

Aaron M. Drucker, MD^1,2; Alexandra G. Ellis, PhD³; Michal Bohdanowicz, MD¹; Soudeh Mashayekhi, MBBS⁴; Zenas Z. N. Yiu, PhD⁵; Bram Rochwerg, MD^6,7; Sonya Di Giorgio, MA⁸; Bernd W. M. Arents⁹; Tim Burton¹⁰; Phyllis I. Spuls, PhD¹¹; Denise Küster, MPH¹²; Doreen Siegels, BSc¹²; Jochen Schmitt, MD¹²; Carsten Flohr, PhD¹³

JAMA Dermatol. Published online April 22, 2020. doi:10.1001/jamadermatol.2020.0796

Key Points

Network Graphs of Studies Included in the Analysis of
Atopic Dermatitis Treatment Between 8 and 16 Weeks

Question  What is the relative effectiveness of systemic treatments for patients with atopic dermatitis?

Findings  This network meta-analysis of 39 randomized clinical trials including 6360 patients found that dupilumab and cyclosporine were similarly effective for adult patients with atopic dermatitis for up to 16 weeks of treatment and were more effective than methotrexate and azathioprine.

Meaning  Cyclosporine and dupilumab may have better short-term effectiveness than methotrexate and azathioprine for patients with atopic dermatitis; this analysis will be updated to add evidence as new medications are approved.

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

Thomas Proctor, 

Elodie Morrough, 

Otto Fenske, 

Sarah Allatt, 

Stephen M. Hughes, 

Vibha Sharma & 

Peter D. Arkwright 

Clinical and Translational Allergy volume 10, Article number: 10 (2020) 

Abstract

Background

Pollen and house dust mite (HDM) subcutaneous immunotherapy (SLIT) and pollen subcutaneous immunotherapy (SCIT) are effective therapies for children with allergic rhinoconjunctivitis (AR). There are no previous direct comparative studies investigating quality of life (QoL) of all three immunotherapy regimes. The aim of this study was to compare QoL and safety in children receiving these immunotherapies for AR.

CME: Differentiating EGPA from Other Eosinophilic Disorders

CME: Differentiating EGPA from Other Eosinophilic Disorders

This activity is supported by an educational grant from GlaxoSmithKline. 

CREDITS: 0.25 CME EXPIRES: 3/29/2021 | MINS: 15 | FEE: $0

Activity Description

In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, discuss the immunopathology and clinical features of eosinophilic granulomatosis with polyangiitis (EGPA), providing guidance on differentiating EGPA from related vasculitides or eosinophilic conditions.

START ACTIVITY

The influence of chlorine in indoor swimming pools on the composition of breathing phase of professional swimmers

• Research
• Open Access
• 
  

• Andrzej S. Swinarew, 
• Arkadiusz J. Stanula, 
• Jadwiga Gabor, 
• Paweł Raif, 
• Jarosław Paluch, 
• Jakub Karpiński, 
• Klaudia Kubik, 
• Hubert Okła, 
• Andrzej Ostrowski, 
• Ewaryst Tkacz, 
• Szymon Skoczyński, 
• Zbigniew Waśkiewicz, 
• Thomas Rosemann, 
• Pantelis T. Nikolaidis & 
• Beat Knechtle 

Respiratory Research volume 21, Article number: 88 (2020)

• details

Abstract

Objectives

Swimming is one of the most popular forms of physical activity. Pool water is cleaned with chlorine, which - in combination with compounds contained in water - could form chloramines and trichloromethane in the swimmer’s lungs. The aim of the present study was to examine the effect of swimming training in an indoor pool on the composition of swimmers’ respiratory phase metabolomics, and develop a system to provide basic information about its impact on the swimmer’s airway mucosa metabolism, which could help to assess the risk of secondary respiratory tract diseases i.e. sport results, condition, and health including lung acute and chronic diseases).

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

RESEARCH ARTICLE

Kai Duan, Bende Liu, Cesheng Li, Huajun Zhang, Ting Yu, Jieming Qu, Min Zhou, Li Chen, Shengli Meng, Yong Hu, Cheng Peng, Mingchao Yuan, Jinyan Huang, Zejun Wang, Jianhong Yu, Xiaoxiao Gao, Dan Wang, Xiaoqi Yu, Li Li, Jiayou Zhang, Xiao Wu, Bei Li, Yanping Xu, Wei Chen, Yan Peng, Yeqin Hu, Lianzhen Lin, Xuefei Liu, Shihe Huang, Zhijun Zhou, Lianghao Zhang, Yue Wang, Zhi Zhang, Kun Deng, Zhiwu Xia, Qin Gong, Wei Zhang, Xiaobei Zheng, Ying Liu, Huichuan Yang, Dongbo Zhou, Ding Yu, Jifeng Hou, Zhengli Shi, Saijuan Chen, Zhu Chen, Xinxin Zhang, and Xiaoming Yang

PNAS first published April 6, 2020 https://doi.org/10.1073/pnas.2004168117

• Article
 
• Figures & SI
 
• Info & Metrics
•  PDF

Significance

COVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explore the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was well tolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 d. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 d. Radiological examination showed varying degrees of absorption of lung lesions within 7 d. These results indicate that CP can serve as a promising rescue option for severe COVID-19, while the randomized trial is warranted.

Abstract

Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 109/L vs. 0.76 × 109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.

 PDF

Last updates and advances of the ALLERGY in ICD-11 initiative + support the community with new coding on COVID-19

We would like to share the last updates and advances of the ALLERGY in ICD-11 initiative + support the community with new coding on COVID-19. As members of the WHO-FIC concild we have received new of coding due to the pandemic and we would like to share with you. 

The ALLERGY in ICD-11 has achieved a lot and we are looking for more advances for our specialty. We thank very much for all the support so far, but now we ask for fast dissemination of the info presented in the attached newsletter in order to provide help to professionals dealing the COVID-19. 

Please find here the Twelfth edition of the ALLERGY in ICD-11 newsletter. We kindly ask you for your support to cascade-down and disseminate the document.

Please stay safe.

With our best wishes,

Luciana & Pascal